Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Types of RNA01:23

Types of RNA

63.4K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
63.4K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated docking-molecular dynamics, ADME-toxicity profiling, and transcriptomic validation identify oroxylin a as a TLR7-targeting flavonoid candidate in systemic lupus erythematosus.

Frontiers in chemistry·2026
Same author

Topical sterosomes-based nanocarrier of miconazole for the management of cutaneous candidiasis.

PloS one·2026
Same author

Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation.

Cancer chemotherapy and pharmacology·2026
Same author

Nanomedicine strategies against multidrug-resistant Acinetobacter baumannii: Delivery, biofilm disruption, and translational considerations.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same author

Targeted nanomedicine strategies for Alzheimer's disease therapy.

Discover nano·2026
Same author

Multi-omics profiling of oxeiptosis-associated biomarkers in cancer.

Clinica chimica acta; international journal of clinical chemistry·2026

Related Experiment Video

Updated: Jun 18, 2025

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

5.9K

Non-coding RNAs in Parkinson's disease: Regulating SNCA and alpha-synuclein aggregation.

Lakshmi Thangavelu1, Ehssan Moglad2, Muhammad Afzal3

  • 1Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, India.

Pathology, Research and Practice
|August 2, 2024
PubMed
Summary

Small RNAs, including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and small interfering RNAs (siRNAs), are key regulators in Parkinson's disease (PD) progression. Targeting these non-coding RNAs offers potential therapeutic strategies for PD by modulating alpha-synuclein aggregation.

Keywords:
Alpha-synuclein aggregationBiomarkerNcRNAsParkinson'sSNCA

More Related Videos

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay
12:55

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay

Published on: June 1, 2014

23.6K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.3K

Related Experiment Videos

Last Updated: Jun 18, 2025

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

5.9K
High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay
12:55

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay

Published on: June 1, 2014

23.6K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.3K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Parkinson's disease (PD) is characterized by alpha-synuclein protein aggregation, driven by elevated SNCA gene expression.
  • Non-coding RNAs (ncRNAs) are increasingly recognized as critical regulators of gene expression and protein aggregation in PD.

Purpose of the Study:

  • To review the roles of long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and small interfering RNAs (siRNAs) in Parkinson's disease.
  • To explore how these ncRNAs regulate SNCA expression and alpha-synuclein aggregation.
  • To highlight the therapeutic potential of targeting ncRNAs for PD treatment.

Main Methods:

  • Literature review of studies on ncRNAs, SNCA gene, and alpha-synuclein in Parkinson's disease.
  • Analysis of mechanisms by which lncRNAs, miRNAs, and siRNAs modulate SNCA expression and protein aggregation.
  • Synthesis of current research on ncRNA-based therapeutic interventions for PD.

Main Results:

  • lncRNAs influence SNCA transcription and epigenetic modifications.
  • miRNAs affect the stability and translation of alpha-synuclein mRNA.
  • siRNAs enable precise gene silencing, downregulating SNCA mRNA.

Conclusions:

  • ncRNAs play multifaceted roles in PD pathogenesis through independent and synergistic mechanisms.
  • Targeting ncRNAs presents a promising avenue for novel drug development in Parkinson's disease.
  • Modulating SNCA expression via ncRNAs could prevent alpha-synuclein aggregation and treat PD.